{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-044623","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2023-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.834231+00:00","generated_at":"2026-06-17T03:13:17.791427+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gain Therapeutics appoints C. Evan Ballantyne as CFO, effective April 10, 2023","bullets":["Appointment: C. Evan Ballantyne named CFO effective April 10, 2023; predecessor Salvatore Calabrese transitions.","Compensation: $350k base salary, 40% target bonus; inducement equity of 100,000 options at $4.79 (4-year vest) and 100,000 performance RSUs.","Performance RSUs: 50,000 vest upon extending cash runway 24 months; 50,000 vest upon stock price reaching $10.00 for 10 days VWAP.","Background: Ballantyne was CFO of OncXerna, Orchestra BioMed, Cerecin; raised millions in equity and structured >$200M partnership."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-044623","json":"https://secwatch.observer/filing/0001104659-23-044623.json","markdown":"https://secwatch.observer/filing/0001104659-23-044623.md","text":"https://secwatch.observer/filing/0001104659-23-044623.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465923044623/0001104659-23-044623-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465923044623/tm2312468d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:13:17.791427+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25f8a96603","claim":"Salvatore Calabrese was terminated as Chief Financial Officer at Gain Therapeutics, Inc..","evidence_excerpt":"the Company informed Salvatore Calabrese, the Company’s former Chief Financial Officer, that his service as Chief Financial Officer of the Company would terminate effective as of the Transition Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465923044623/0001104659-23-044623-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c3b07bf38e","claim":"C. Evan Ballantyne was appointed as Chief Financial Officer at Gain Therapeutics, Inc..","evidence_excerpt":"announced the appointment of C. Evan Ballantyne as its Chief Financial Officer, effective as of April 10, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465923044623/0001104659-23-044623-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}